264 related articles for article (PubMed ID: 38676539)
1. Tezepelumab: patient selection and place in therapy in severe asthma.
Menzella F; Munari S; Corsi L; Tonin S; Cestaro W; Ballarin A; Floriani A; Dartora C; Senna G
J Int Med Res; 2024 Apr; 52(4):3000605241246740. PubMed ID: 38676539
[TBL] [Abstract][Full Text] [Related]
2. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option?
Menzies-Gow A; Wechsler ME; Brightling CE
Respir Res; 2020 Oct; 21(1):268. PubMed ID: 33059715
[TBL] [Abstract][Full Text] [Related]
3. Tezepelumab in patients with allergic and eosinophilic asthma.
Caminati M; Buhl R; Corren J; Hanania NA; Kim H; Korn S; Lommatzsch M; Martin N; Matucci A; Nasser SM; Pavord ID; Domingo C
Allergy; 2024 May; 79(5):1134-1145. PubMed ID: 38146651
[TBL] [Abstract][Full Text] [Related]
4. CASCADE: a phase 2, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the effect of tezepelumab on airway inflammation in patients with uncontrolled asthma.
Emson C; Diver S; Chachi L; Megally A; Small C; Downie J; Parnes JR; Bowen K; Colice G; Brightling CE
Respir Res; 2020 Oct; 21(1):265. PubMed ID: 33050900
[TBL] [Abstract][Full Text] [Related]
5. Tezepelumab: a novel biological therapy for the treatment of severe uncontrolled asthma.
Marone G; Spadaro G; Braile M; Poto R; Criscuolo G; Pahima H; Loffredo S; Levi-Schaffer F; Varricchi G
Expert Opin Investig Drugs; 2019 Nov; 28(11):931-940. PubMed ID: 31549891
[No Abstract] [Full Text] [Related]
6. Tezepelumab as an Emerging Therapeutic Option for the Treatment of Severe Asthma: Evidence to Date.
Dorey-Stein ZL; Shenoy KV
Drug Des Devel Ther; 2021; 15():331-338. PubMed ID: 33536746
[TBL] [Abstract][Full Text] [Related]
7. Thymic Stromal Lymphopoietin and Tezepelumab in Airway Diseases: From Physiological Role to Target Therapy.
Bagnasco D; De Ferrari L; Bondi B; Candeliere MG; Mincarini M; Riccio AM; Braido F
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892164
[TBL] [Abstract][Full Text] [Related]
8. Tezepelumab for Severe Asthma: One Drug Targeting Multiple Disease Pathways and Patient Types.
Panettieri R; Lugogo N; Corren J; Ambrose CS
J Asthma Allergy; 2024; 17():219-236. PubMed ID: 38524099
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and Pharmacodynamic Modeling of Tezepelumab to Guide Phase 3 Dose Selection for Patients With Severe Asthma.
Ly N; Zheng Y; Griffiths JM; van der Merwe R; Agoram B; Parnes JR; Roskos L
J Clin Pharmacol; 2021 Jul; 61(7):901-912. PubMed ID: 33368307
[TBL] [Abstract][Full Text] [Related]
10. Current summary of clinical studies on anti-TSLP antibody, Tezepelumab, in asthma.
Kurihara M; Kabata H; Irie M; Fukunaga K
Allergol Int; 2023 Jan; 72(1):24-30. PubMed ID: 36470789
[TBL] [Abstract][Full Text] [Related]
11. Tezepelumab for asthma.
Nolasco S; Pelaia C; Scioscia G; Campisi R; Crimi C
Drugs Today (Barc); 2022 Dec; 58(12):591-603. PubMed ID: 36651067
[TBL] [Abstract][Full Text] [Related]
12. Positioning of Tezepelumab in Severe Asthma.
Miralles-López JC; Antolín-Amérigo D; García-Moguel I; Domínguez-Ortega J; Delgado-Romero J; Quirce S
J Investig Allergol Clin Immunol; 2024 Feb; 34(1):1-11. PubMed ID: 37812191
[TBL] [Abstract][Full Text] [Related]
13. Tezepelumab: an anti-thymic stromal lymphopoietin monoclonal antibody for the treatment of asthma.
Shinkai M; Yabuta T
Immunotherapy; 2023 Dec; 15(17):1435-1447. PubMed ID: 37724378
[TBL] [Abstract][Full Text] [Related]
14. Promises and challenges of biologics for severe asthma.
Tan R; Liew MF; Lim HF; Leung BP; Wong WSF
Biochem Pharmacol; 2020 Sep; 179():114012. PubMed ID: 32389637
[TBL] [Abstract][Full Text] [Related]
15. Thymic stromal lymphopoietin and alarmins as possible therapeutical targets for asthma.
Salvati L; Maggi L; Annunziato F; Cosmi L
Curr Opin Allergy Clin Immunol; 2021 Dec; 21(6):590-596. PubMed ID: 34608100
[TBL] [Abstract][Full Text] [Related]
16. Sounding the alarmins-The role of alarmin cytokines in asthma.
Gauvreau GM; Bergeron C; Boulet LP; Cockcroft DW; Côté A; Davis BE; Leigh R; Myers I; O'Byrne PM; Sehmi R
Allergy; 2023 Feb; 78(2):402-417. PubMed ID: 36463491
[TBL] [Abstract][Full Text] [Related]
17. Molecular Targets for Biological Therapies of Severe Asthma.
Pelaia C; Crimi C; Vatrella A; Tinello C; Terracciano R; Pelaia G
Front Immunol; 2020; 11():603312. PubMed ID: 33329598
[TBL] [Abstract][Full Text] [Related]
18. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma.
Gauvreau GM; Sehmi R; Ambrose CS; Griffiths JM
Expert Opin Ther Targets; 2020 Aug; 24(8):777-792. PubMed ID: 32567399
[TBL] [Abstract][Full Text] [Related]
19. Tezepelumab: A Potential New Biological Therapy for Severe Refractory Asthma.
Pelaia C; Pelaia G; Crimi C; Maglio A; Gallelli L; Terracciano R; Vatrella A
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922072
[TBL] [Abstract][Full Text] [Related]
20. DESTINATION: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the long-term safety and tolerability of tezepelumab in adults and adolescents with severe, uncontrolled asthma.
Menzies-Gow A; Ponnarambil S; Downie J; Bowen K; Hellqvist Å; Colice G
Respir Res; 2020 Oct; 21(1):279. PubMed ID: 33087119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
